Antiva Biosciences last raised $38.5M in its Early Stage VC (Apr 2023).
- ·The complete investor list: 21 names
- ·Watch Antiva Biosciences: the Monday email on marks, rounds and moves
Antiva Biosciences funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Apr 2023 | Early Stage VC | $38.5M | ▮ | ▮ |
| Oct 2021 | Early Stage VC | $15.6M | ▮ | ▮ |
| Jul 2018 | Early Stage VC | $15.0M | ▮ | ▮ |
| Feb 2017 | Early Stage VC | $14.7M | ▮ | ▮ |
Membership and data by Private Market View
Antiva Biosciences valuation
Antiva Biosciences's last known valuation is $123 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Antiva Biosciences raised?
Antiva Biosciences has raised $145 million across 4 recorded rounds since 2017. The largest was a $38.5 million early-stage round in Apr 2023.
Antiva Biosciences has filed 6 Form Ds with the SEC since 2017, most recently in Oct 2024 ($38.5 million sold to 21 investors).
How Antiva Biosciences's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Antiva Biosciences, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked about Antiva Biosciences
- What is Antiva Biosciences worth?
- Antiva Biosciences's last known valuation is $123.0M.
- How much has Antiva Biosciences raised?
- Antiva Biosciences has raised $144.8M in total funding across 4 recorded rounds.
- When did Antiva Biosciences last raise?
- Antiva Biosciences last raised in Apr 2023 (Early Stage VC), raising $38.5M.